ClinicaliQ Trial Snapshot
- Manganese-enhanced Magnetic Resonance Imaging (MEMRI) in Heart Failure With Preserved Ejection Fraction — Recruiting • Cardiology / Cardiovascular • NCT06652763.
- What is being tested: Manganese-enhanced Magnetic Resonance Imaging (MEMRI) as a novel imaging technique to visualise cardiac function and myocardial viability in heart failure with preserved ejection fraction (HFpEF), where conventional imaging has limited diagnostic utility.
- Patient eligibility overview: Adults with confirmed HFpEF diagnosis (normal or near-normal left ventricular ejection fraction despite symptoms of heart failure) who are able to undergo MRI scanning and provide informed consent; typically excludes those with contraindications to MRI or manganese contrast agents.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
Heart failure with preserved ejection fraction (HFpEF) is a condition in which the heart cannot fill with blood effectively. As a result, people with HFpEF suffer fatigue, breathlessness, and develop swollen limbs. The condition often requires multiple admissions to hospital and is associated with a marked loss of lifespan. Despite being so common, very little is known about why people develop HFpEF and there are hardly any known treatments. Type 2 diabetes (T2D) is a major risk factor for HFpEF, and people with both HFpEF and diabetes are at a…
Eligibility Snapshot
- : * Capacity to provide informed consent * Symptoms (e.g. breathlessness, orthopnoea, ankle swelling, fatigue), signs (e.g. elevated jugular venous pressure, peripheral oedema, third heart sound) or established diagnosis of HF with LV ejection fraction ≥ 50%, or * Meets HFpEF diagnostic criteria in accordance with the HFA-PEFF diagnostic algorithm form the Heart Failure Association of the European Society of Cardiology, in which a score ≥5 points confirms diagnosis of HFpEF
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.